Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review.
Fiche publication
Date publication
février 2016
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Fiteni F, Anota A, Westeel V, Bonnetain F
Lien Pubmed
Résumé
Health-related quality of life (HRQoL) is recognized as a component endpoint for cancer therapy approvals. The aim of this review was to evaluate the methodology of HRQoL analysis and reporting in phase III clinical trials of first-line chemotherapy in advanced non-small cell lung cancers (NSCLC).
Mots clés
Carcinoma, Non-Small-Cell Lung, drug therapy, Clinical Trials, Phase III as Topic, Humans, Linear Models, Lung Neoplasms, drug therapy, Quality of Life, Surveys and Questionnaires
Référence
BMC Cancer. 2016 Feb;16:122